Latest Content

ODs are gearing up for anticipated advancements in specialty lens and lenses for myopia management and patients with astigmatism.

Kuzniar's OGSLS 2026 poster presentation provides a follow-up to previous fitting findings for the Zenlens Chroma HOA lens.

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, age-related macular degeneration, and rare eye diseases.

A total of 38 patients were included in the study. All underwent implantation of the PRIMAretinal prosthetic chip with the goal of restoring vision.

The state of the eye’s surface is just as important a factor as accurate measurements when determining the correct IOL.

Jason Jedlicka, OD, FAAO, talks through a presentation he gave during last week's conference.

Previously, the EDOF technology was specifically limited to intraocular lenses.

Employers are obliged to provide employees with appropriate safety eyewear and face protection that conforms to the industry standard.

Chronic ocular diseases and ocular surface diseases alike now have new treatment options.

Susan Gromacki, OD, MS, FAAO, FSLS, details her presentation given at this year's conference.

Jamie Kuzniar, OD, FAAO, FSLS, details a poster presentation that served as a follow-up to results of previous fittings of Zenlens Chroma HOA (Bausch + Lomb).

Jason Jedlicka, OD, overviews his poster, “A Custom Wavefront-Guided Scleral Lens System For Higher Order Aberrations: Real-World Early Experience From a Retrospective Multicenter Case Review.”

New clinical data and trial updates closed out 2025.